Khalid S Abu Khabar

USPTO Granted Patents = 8 (Patent Applications = 6)

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 1.1

ph-index = 1

Forward Citations = 2(Granted Patents)

Company Filing History:

7 out of 27

King Faisal Specialist Hospital & Research Centre

patents

1 out of 5

King Faisal Specialist Hospital and Research Center

patents

Years Active: 2014-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12295955 - TTP phosphorylation for the identification of personalized medicines (2025-05-13),

2. 11649504 - Set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival (2023-05-16),

3. 11648251 - TTP phosphorylation as a biomarker in targeted therapy (2023-05-16),

4. 9279021 - Method for increasing the expression and/or stability of a protein in a cell and a peptide for use in such method (2016-03-08),

5. 9017965 - Hybrid 3' untranslated regions suitable for efficient protein expression in mammalian cells (2015-04-28),

6. 8795962 - Expression vectors based on modified ribosomal protein promoters and uses thereof in post-transcriptional assessment (2014-08-05),

7. 8791241 - Fluorescent proteins with increased activity in cells (2014-07-29),

8. 8680256 - Methods for producing inducible and/or repressible expression active linear RNA interference cassettes and inducible and/or repressible expression active linear gene cassettes and their uses (2014-03-25),

Title: Innovator Khalid S. Abu Khabar: Pioneering Personalized Medicine

Introduction

Khalid S. Abu Khabar, an accomplished inventor based in Riyadh, Saudi Arabia, has made significant contributions to the field of personalized medicine. With a total of eight patents to his name, Khalid has focused on methods and treatments that enhance the efficacy of cancer therapy, aiming to cater to individual patient needs.

Latest Patents

Among Khalid's latest inventions is a groundbreaking patent titled "TTP Phosphorylation for the Identification of Personalized Medicines." This invention details a method to determine how likely patients are to respond to targeted therapy compounds, including protein kinase inhibitors, small molecule inhibitors, and monoclonal antibody-based compounds. Additionally, it presents a methodology for treating cancer in patients with these targeted therapies.

He has also developed a patent titled "Set of Genes for Use in a Method of Predicting the Likelihood of a Breast Cancer Patient's Survival." This inventive methodology is designed to predict the likelihood of survival, recurrence, and aggressiveness of breast cancer in patients, further enhancing the landscape of personalized treatment approaches.

Career Highlights

Khalid has garnered valuable experience working with prestigious institutions such as King Faisal Specialist Hospital & Research Centre and King Faisal Specialist Hospital and Research Center. His work in these environments has been instrumental in shaping his innovative approaches to tackling critical health issues.

Collaborations

Throughout his career, Khalid has collaborated with esteemed colleagues such as Tala Bakheet and Edward Hitti. These partnerships have allowed for a fruitful exchange of ideas and an enriched research environment, contributing further to the advancements in personalized medicine.

Conclusion

Khalid S. Abu Khabar's innovative spirit and dedication to improving patient care through personalized medicine signify his vital role as an inventor in the medical field. His patents are a testament to his commitment to reducing the uncertainty in cancer treatments, ultimately aiming to enhance patient outcomes and survival rates.

This text is generated by artificial intelligence and may not be accurate.